ES2043831T3 - Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos. - Google Patents

Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos.

Info

Publication number
ES2043831T3
ES2043831T3 ES88307307T ES88307307T ES2043831T3 ES 2043831 T3 ES2043831 T3 ES 2043831T3 ES 88307307 T ES88307307 T ES 88307307T ES 88307307 T ES88307307 T ES 88307307T ES 2043831 T3 ES2043831 T3 ES 2043831T3
Authority
ES
Spain
Prior art keywords
hepatitis
virus
purine
dideoxinucleoxides
hepadenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307307T
Other languages
English (en)
Inventor
David L J Tyrrell
Morris J Robins
Satoru Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Application granted granted Critical
Publication of ES2043831T3 publication Critical patent/ES2043831T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE INFECCIONES DE HEPADENOVIRUS EN ANIMALES. LOS ANIMALES INFECTADOS POR EL VIRUS DE LA HEPATITIS B HAN DE SER TRATADOS CON LOS 2'',3''DIDEOXINUCLEOXIDOS DE ADENINA, GUANINA, HIPOXANTINA, 2,6 DIAMINOPURINA O VARIOS ANALOGOS DE PURINAS SUSTITUIDAS. VARIOS ANALOGOS 2'',3''- DIDEOXINUCLEOXIDOS DE PURINA INHIBEN AL VIRUS DE LA HEPATITIS B EN CULTIVOS DE HEPATOCITOS > 99% A 1(MU)G/ML. SE DEMUESTRA LA EFICACIA POTENTE EN VIVO DE LA 2,6 - DIAMINO PURINA 2'',3''-DIDEOXINUCLEOXIDO PARA LA ELIMINACION DEL VIRUS DE LA HEPATITIS B DE PATO EN SUERO DE PATOS DE PEKIN.EL EFECTO SELECTIVO SOBRE LA REPLICACION DE HEPADENOVIRUS POR LOS 2'',3''-DEOXINUCLEOXIDOS DE PURINA SE BASA EN EL DESCUBRIMIENTO DE UNA INESPERADA SENSIBILIDAD DE ESTOS A LOS ANALOGOS ANTES MENCIONADOS. ESTOS COMPUESTOS PERMITEN UNA TERAPIA ANTIVIRICA PARA CASOS DE INFECCION AGUDA O PERSISTENTE POR HEPADENOVIRUS.
ES88307307T 1987-08-07 1988-08-08 Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos. Expired - Lifetime ES2043831T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17819687A 1987-08-07 1987-08-07

Publications (1)

Publication Number Publication Date
ES2043831T3 true ES2043831T3 (es) 1994-01-01

Family

ID=22651606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307307T Expired - Lifetime ES2043831T3 (es) 1987-08-07 1988-08-08 Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos.

Country Status (9)

Country Link
EP (1) EP0302760B1 (es)
JP (1) JP2899292B2 (es)
KR (1) KR940010441B1 (es)
AT (1) ATE78692T1 (es)
AU (1) AU623341B2 (es)
CA (1) CA1327000C (es)
DE (1) DE3873207T2 (es)
ES (1) ES2043831T3 (es)
HK (1) HK1000112A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
CA2054771A1 (en) * 1989-05-15 1990-11-16 Hiroaki Mitsuya Method of treatment of hepatitis
WO1990014079A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
DE4110977A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Substituierte 2',3'-didesoxy-5-trifluormethyluridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions

Also Published As

Publication number Publication date
AU2050288A (en) 1989-02-09
EP0302760A2 (en) 1989-02-08
JP2899292B2 (ja) 1999-06-02
CA1327000C (en) 1994-02-15
EP0302760A3 (en) 1989-08-09
KR890003384A (ko) 1989-04-14
HK1000112A1 (en) 1997-12-05
DE3873207T2 (de) 1993-01-07
JPH0285215A (ja) 1990-03-26
EP0302760B1 (en) 1992-07-29
ATE78692T1 (de) 1992-08-15
KR940010441B1 (ko) 1994-10-22
DE3873207D1 (en) 1992-09-03
AU623341B2 (en) 1992-05-14

Similar Documents

Publication Publication Date Title
ATE135365T1 (de) Antivirale verbindungen
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
PA8483101A1 (es) Compuestos quimicos
AU4690989A (en) Antiviral cytosine and guanine derivatives
ES2091750T3 (es) Compuestos antivirales.
DK224286A (da) 2',3'-dideoxy-nucleosider
ES2087639T3 (es) Nucleosidos terapeuticos.
ES8802616A1 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
Shigeta et al. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro
Hosoya et al. Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro
KR870006900A (ko) 항바이러스 조성물
ATE78692T1 (de) Antivirale therapie gegen hepatitis b mit 2',3'- didesoxynucleosiden.
BG100599A (en) Antiviral form and therapeutical method
DK615788D0 (da) Nucleosidforbindelser til anvendelse mod virale infektioner
Meldrum et al. Cell culture studies on the antiviral activity of ether derivatives of 5-hydroxymethyldeoxyuridine
Connell et al. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice
ATE183508T1 (de) Therapeutische nukleoside
DE68914809D1 (de) Antivirale Wirkstoffe.
Thompson et al. Effect of Ethionine and Other Materials on Semliki Forest Virus Infection in the Mouse.
Rada et al. Virus inhibitory activity of some pyrimidine derivatives and trimethinium salts in tissue culture
Upadhyay et al. The effect of HSV multiplication rate on antiviral drug efficacy in vitro
PY990158A (es) Nucleosidos terapeuticos
Dianzani et al. Antiviral Drugs
KR950703976A (ko) 아시클로비르 유사 화합물과 2′-비닐 치환 뉴클레오시드 유사체를 함유하는 바이러스 감염 치료용 조성물(Compositions Containing Acyclovir-Like Compounds and 2′-Vinyl substituted Nucleoside Analogs for the Treatment of Viral Infections)
KR890001560A (ko) 항바이어러스 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 302760

Country of ref document: ES